Open main menu

Template:Clinical dosage ranges of oral and injectable androgens and anabolic steroids

Clinical dosage ranges of oral and injectable androgens and anabolic steroids

Route Medication Major brand names Dosage range
Oral Danazol Danocrine 100–800 mg/day
Ethylestrenol Maxibolin, Orabolin 2–8 mg/day
Fluoxymesterone Halotestin, Ora-Testryl, Ultandren 2–40 mg/day
Mesterolone Proviron 25–150 mg/day
Metandienone Dianabol 2.5–15 mg/day
Metenolone acetate Primobolan 10–150 mg/day
Methyltestosterone Android, Metandren, Testred 1.5–200 mg/day
Norethandrolone Nilevar, Pronabol 20–30 mg/day
Oxandrolone Anavar, Oxandrin 2.5–20 mg/day
Oxymetholone Anadrol, Anapolon 1–5 mg/kg/day (50–150 mg/day)
Stanozolol Winstrol 2–6 mg/day
Testosteronea 400–800 mg/day (in divided doses)
Testosterone undecanoate Andriol, Jatenzo 40–80 mg/2–4x day (with food)
Injection Drostanolone propionate Drolban, Masteril, Masteron 100 mg 3x/week
Metenolone enanthate Primobolan Depot 25–100 mg/week
Nandrolone decanoate Deca-Durabolin 12.5–200 mg/week (total)
Nandrolone phenylpropionate Durabolin 6.25–200 mg/week (total)
Stanozolol Winstrol Depot 50 mg 1x/2–3 weeks
Testosterone Andronaq, Sterotate, Virosterone 25–100 mg 2–3x/week
Testosterone cypionate Depo-Testosterone 50–400 mg 1x/1–4 weeks
Testosterone enanthate Delatestryl 50–400 mg 1x/1–4 weeks
Testosterone propionate Testoviron 25–50 mg 2–3x/week
Testosterone undecanoate Aveed, Nebido 750–1,000 mg 1x/10–14 weeks
Trenbolone hexahydrobenzylcarbonate Hexabolan, Parabolan 75 mg/1.5 weeks
Note: Dosage ranges are for varying indications and are not necessarily equivalent. Footnotes: a = Studied for male hypogonadism but never marketed. For comparison purposes. Sources: General: [1][2][3][4][5][6][7][8] Additional: [9][10]
Template documentation

See also

References

  1. ^ "Drugs@FDA: FDA Approved Drug Products". United States Food and Drug Administration. Retrieved 1 December 2019.
  2. ^ Richard Joseph Hamilton; Nancy Anastasi Duffy; Daniel Stone (2014). Tarascon Pharmacopoeia. Jones & Bartlett Publishers. pp. 174–. ISBN 978-1-284-05671-6.
  3. ^ Susan M. Ford; Sally S. Roach (2010). Roach's Introductory Clinical Pharmacology. Lippincott Williams & Wilkins. pp. 499–. ISBN 978-1-60547-633-9.
  4. ^ Thomas L. Lemke; David A. Williams (24 January 2012). Foye's Principles of Medicinal Chemistry. Lippincott Williams & Wilkins. pp. 1358–. ISBN 978-1-60913-345-0.
  5. ^ Brent C Mangus; Michael G Miller (11 January 2005). Pharmacology Application in Athletic Training. F.A. Davis. pp. 151–. ISBN 978-0-8036-2027-8.
  6. ^ John A. Thomas (6 December 2012). Drugs, Athletes, and Physical Performance. Springer Science & Business Media. pp. 20–. ISBN 978-1-4684-5499-4.
  7. ^ William Llewellyn (2011). Anabolics. Molecular Nutrition Llc. ISBN 978-0-9828280-1-4.
  8. ^ Burkett, Lee N.; Falduto, Michael T. (1984). "Steroid Use by Athletes in a Metropolitan Area". The Physician and Sportsmedicine. 12 (8): 69–74. doi:10.1080/00913847.1984.11701923. ISSN 0091-3847.
  9. ^ J. Bain; Wolf-Bernhard Schill; L. Schwarzstein (6 December 2012). Treatment of Male Infertility. Springer Science & Business Media. pp. 176–177. ISBN 978-3-642-68223-0.
  10. ^ Snyder, P J (1984). "Clinical Use of Androgens". Annual Review of Medicine. 35 (1): 207–217. doi:10.1146/annurev.me.35.020184.001231. ISSN 0066-4219.